• male or female subjects ≥ 18 years of age at the time of signing ICF.

• histologically or cytologically confirmed diagnosis of non-radical, locally advanced (Stage IIIB and IIIC) or metastatic (Stage IV) non-squamous cell type NSCLC (refer to the American Joint Committee on Cancer \[AJCC\] Lung Cancer Stages, 8th edition for lung cancer staging criteria).

• Part 1 (introductory stage) MET amplification is defined as the presence of MET amplification confirmed by second-generation sequencing (NGS) or fluorescence in situ hybridization (FISH) with a mean MET GCN ≥ 4 cells/cell or MET/CEP7 ≥ 2, and subjects are required to provide sufficient tumor tissue (archived or fresh samples) for retrospective analysis in the central laboratory (see Laboratory Manual) to support the development of concomitant diagnostic reagents required for the marketing of Vebreltinib. Part 2 (Randomized Control Phase) MET amplification is defined as subjects' tumor tissue (archived or fresh samples) with an average MET GCN ≥ 4 cells/cell or MET/CEP7 ≥ 2 as confirmed by fluorescence in situ hybridization (FISH) in the central laboratory, and subjects will be required to provide sufficient tumor tissue (archived or fresh samples) for retrospective assay analysis by a central laboratory (see Laboratory Manual). Laboratory Manual) to support the development of concomitant diagnostic reagents required for the marketing of Vebreltinib.

• documented evidence of negative tumor tissue samples for other driver genes, including: epidermal growth factor receptor (EGFR) wild-type, ALK rearrangement negative, ROS1 rearrangement negative, KRAS mutation negative, NTRK rearrangement negative, BRAF mutation negative, RET fusion negative, MET exon 14 jump mutation negative, ERBB2 (HER-2) mutation Negative for ERBB2 (HER-2) mutation.

• no prior systemic therapy for locally advanced or metastatic non-squamous NSCLC. Note: Subjects are permitted to receive neoadjuvant/adjuvant therapy as long as the relevant therapy has been completed for at least 6 months prior to disease diagnosis of locally progressive or metastatic tumor.

• at least one measurable target lesion as defined by the Response to Criteria for Evaluation of Efficacy in Solid Tumors (RECIST) V1.1 criteria (see Chapter 10.4).

• ECOG PS ≤ 1.

• expected survival ≥ 12 weeks as determined by the investigator.

• good organ function as determined by medical evaluation (within 7 days prior to first study dose), including:

‣ Good hematologic status, defined as absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L, hemoglobin ≥ 90 g/L, platelets ≥ 100 x 10\^9/L. No platelet transfusions within 3 days prior to the test, no red blood cell transfusions within 14 days prior to the test, and no hematopoietic growth factor therapy within 7 days prior to the test (polyethylene glycolated granulocyte colony-stimulating factor \[G-CSF\] or erythropoietin \[EPO\] within 14 days prior to testing).

⁃ Good hepatic function, defined as serum TBIL ≤ 1.5 x ULN (TBIL ≤ 3 x ULN and direct bilirubin \[DBIL\] ≤ 1.5 x ULN in subjects known to have Gilbert's syndrome), serum ALT/AST ≤ 2.5 x ULN (≤ 5.0 x ULN for subjects with confirmed liver metastases) .

⁃ Good renal function, defined as: creatinine \<1.5 x ULN or creatinine clearance \>50 mL/min (calculated by the Cockcroft-Gault formula).

⁃ Good coagulation function, defined as (including when receiving anticoagulation): prothrombin time (PT) \< 1.5 x ULN and activated partial thromboplastin time (APTT) \< 1.5 x ULN If subjects are receiving anticoagulant therapy, they must have received a stabilized dose of anticoagulant for at least 1 month prior to the first study dose.

⁃ Female subjects must be using adequate contraception and not breastfeeding during study participation and for 90 days after completion of study treatment; female subjects of childbearing potential must have had a serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test performed within 7 days prior to the first dose of the drug and be negative; and female subjects of no childbearing potential must meet one of the following criteria at screening:

∙ Reached postmenopausal status, refer to the NCCN Breast Cancer Guidelines (2024 V3.0) for a detailed definition of menopause.

‣ Have undergone and documented irreversible sterilization such as hysterectomy, bilateral salpingo-oophorectomy, or bilateral salpingo-oophorectomy (not tubal ligation).

⁃ Male subjects of childbearing potential must use adequate contraception (e.g., barrier methods of contraception) during study participation and for 90 days after completion of study treatment. Male subjects must also refrain from sperm donation during study participation and for 90 days after the last dose of study treatment.

⁃ be able to provide a signed ICF that complies with the requirements and restrictions outlined in the ICF and this study protocol.